CClinicalTrials.gg
CompletedNCT07490470Updated Mar 24, 2026

Nurse-Led mHealth for Vulnerable-Phase Heart Failure

An interventional study of Nurse-Led mHealth Multidisciplinary Management and Routine Outpatient Follow-Up in Heart Failure, sponsored by Peking University First Hospital. Completed at 1 site in China. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Jun 2022, registered Mar 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
Up to 80 Years
Sex
All
01

Study summary

Heart failure is a serious condition where the heart cannot pump blood as well as it should. After being discharged from the hospital, patients with heart failure are at high risk for readmission, especially in the first three months. This period is called the "vulnerable phase." Standard care often involves follow-up visits, but patients may struggle to manage their health at home.

This study tested a new approach to care. The program is led by a nurse and uses a mobile health (mHealth) application on a smartphone. The app helps patients manage their health by providing daily medication reminders, tracking their weight and symptoms, and offering educational information. A team of doctors, pharmacists, and nurses work together to monitor patient data through the app. If any concerning signs appear, the team discusses the case and provides timely guidance to the patient.

The study enrolled 100 patients with heart failure. Half of them received this nurse-led, app-based program in addition to their regular follow-up care. The other half received only the regular follow-up care. We measured how well patients managed their own care, how they felt (their symptoms), and key health indicators like heart function and a blood marker called NT-proBNP. We compared the two groups after three months.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's enrollment of 104 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

(1) meeting the diagnostic criteria for heart failure according to the 2024 Chinese guidelines for heart failure diagnosis and treatment; (2) ability to participate in heart failure follow-up management at the outpatient clinic; (3) left ventricular ejection fraction ≤ 50%; (4) age ≤ 80 years; (5) proficiency in smartphone use by either the patient or their caregiver; and (6) adequate reading comprehension and verbal communication skills.

Exclusion criteria

Exclusion Criteria:

(1) had other life-threatening conditions (e.g., malignancy, end-stage renal disease); or (2) exhibited severe physical impairment.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Nurse-Led mHealth Multidisciplinary Management

    Behavioral: Nurse-Led mHealth Multidisciplinary Management

  • Active comparator
    Routine Outpatient Follow-Up

    Behavioral: Routine Outpatient Follow-Up

Interventions

  • BehavioralNurse-Led mHealth Multidisciplinary Management

    The intervention group received a nurse-led, multidisciplinary program via the Cardiovascular Home Care APP, in addition to conventional follow-up care. Team: 4 physicians, 4 nurses, and APP use. 1.Pre-discharge APP training: daily tasks, report upload, online consultation. APP automatically linked to patient information upon discharge.2.Nurse-created plans: medication schedules, self-monitoring (BP/heart rate/weight/symptoms), follow-up appointments, with reminders.3.Regular tailored education via APP (trigger avoidance, risk control, sodium/fluid restriction, symptom recognition, exercise).4.Daily nurse monitoring via backend. Alerts (non-adherence ≥7 days; BP fluctuation \>20%; medication intolerance; weight gain \>2kg/3 days; volume overload symptoms) triggered nurse contact and multidisciplinary discussion for treatment adjustments.5.Structured telephone follow-up at week 1; additional calls as needed.6.Dynamic plan updates during clinic visits.

  • BehavioralRoutine Outpatient Follow-Up

    Participants in the control group received conventional follow-up care. This consisted of standard outpatient clinic visits at 2 weeks, 1 month, 2 months, and 3 months after hospital discharge. The follow-up clinic was operated by a dedicated "physician-pharmacist-nurse" team. During these visits, the physician conducted clinical assessments and adjusted treatments as necessary. In the intervals between physician consultations, the pharmacist and nurse performed evaluations of disease knowledge and self-care behaviors, delivering individualized health education. Patients were provided with a health education handbook containing information about heart failure and logs for recording blood pressure, heart rate, body weight, and self-reported symptoms. They also received instruction on how to perform self-monitoring and apply the results to guide their self-care practices.

06

What researchers measure

Primary outcomes

  1. Self-Care of Heart Failure Index (SCHFI) Scores

    The SCHFI consists of three subscales: (1) Self-Care Maintenance (10 items), which assesses treatment adherence and symptom monitoring using a 4-point Likert scale (1-4); (2) Self-Care Management (6 items), which evaluates symptom recognition (one item, 5-point Likert scale 0-4), symptom management (four items, 4-point Likert scale 1-4), and evaluation of management strategies (one item, 5-point Likert scale 0-4); and (3) Self-Care Confidence (6 items), which measures confidence in maintaining self-care (two items) and managing symptoms (four items) using a 4-point Likert scale (1-4). Each subscale is converted to a standardized score ranging from 0 to 100 using the formula: \[(raw score - minimum score) / (maximum score - minimum score)\] × 100. The total score is the sum of the three subscale scores (range 0-300), with higher scores indicating better self-care. The Chinese version has demonstrated good reliability, with Cronbach's α coefficients ranging from 0.656 to 0.869 for the sub

    Time frame: Baseline, Month 3

Secondary outcomes

  1. The Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF)

    This 32-item instrument evaluates symptoms across three subscales: physical symptoms, psychological symptoms, and heart failure-specific symptoms. For each symptom, four dimensions are assessed: presence, frequency (1-4 point Likert scale), severity (1-4 point Likert scale), and distress (0-4 point Likert scale). If a symptom is not present, it is scored as "0". The total symptom score is calculated as the mean of all symptom scores, with higher scores indicating greater symptom burden. The Chinese version has shown excellent reliability, with Cronbach's α coefficients ranging from 0.807 to 0.946 for the total scale and subscales.

    Time frame: Baseline, Month 3

  2. NYHA Functional Class

    NYHA classification is a widely used clinical tool for evaluating the functional status of heart failure patients, reflecting symptom severity and limitations in physical activity.

    Time frame: Baseline, Month 3

  3. B-type natriuretic peptide (BNP)

    BNP measurement is utilized for heart failure screening, diagnosis, differential diagnosis, and assessment of disease severity and prognosis. Pre-discharge BNP levels are particularly valuable for stratifying the risk of subsequent cardiovascular events following hospital discharge.

    Time frame: Baseline, Month 3

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
08

References and documents

Publications

  • Freedman G, Watt R, Chowdhury EK, Quinlan K, Eccleston D, Driscoll A, Theuerle J, Kearney L. Nurse-Led, Remote Optimisation of Guideline-Directed Medical Therapy in Patients with Heart Failure and Reduced Ejection Fraction Across Australia. J Clin Med. 2025 Jul 30;14(15):5371. doi: 10.3390/jcm14155371. PubMed 40806994 ↗
  • Son YJ, Choi J, Lee HJ. Effectiveness of Nurse-Led Heart Failure Self-Care Education on Health Outcomes of Heart Failure Patients: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020 Sep 9;17(18):6559. doi: 10.3390/ijerph17186559. PubMed 32916907 ↗
  • Man JP, Dijkgraaf MGW, Handoko ML, de Lange FJ, Winter MM, Schijven MP, Stienen S, Meregalli P, Kok WEM, Kuipers DI, van der Harst P, Koole MAC, Chamuleau SAJ, Schuuring MJ. Digital consults to optimize guideline-directed therapy: design of a pragmatic multicenter randomized controlled trial. ESC Heart Fail. 2024 Feb;11(1):560-569. doi: 10.1002/ehf2.14634. Epub 2023 Dec 26. PubMed 38146630 ↗
  • Ozden F, Sari Z, Karaman ON, Aydogmus H. The effect of video exercise-based telerehabilitation on clinical outcomes, expectation, satisfaction, and motivation in patients with chronic low back pain. Ir J Med Sci. 2022 Jun;191(3):1229-1239. doi: 10.1007/s11845-021-02727-8. Epub 2021 Aug 6. PubMed 34357527 ↗
  • Zheng J, Mednick T, Heidenreich PA, Sandhu AT. Pharmacist- and Nurse-Led Medical Optimization in Heart Failure: A Systematic Review and Meta-Analysis. J Card Fail. 2023 Jul;29(7):1000-1013. doi: 10.1016/j.cardfail.2023.03.012. Epub 2023 Mar 31. PubMed 37004867 ↗
  • Bezerra Giordan L, Tong HL, Atherton JJ, Ronto R, Chau J, Kaye D, Shaw T, Chow C, Laranjo L. The Use of Mobile Apps for Heart Failure Self-management: Systematic Review of Experimental and Qualitative Studies. JMIR Cardio. 2022 Mar 31;6(1):e33839. doi: 10.2196/33839. PubMed 35357311 ↗
  • Zare-Kaseb A, Emami Zeydi A, Bakhtiari-Dovvombaygi H, Nazari AM. Effects of education based on teach-back methods on self-care and quality of life of the patients with heart failure: a systematic review. BMC Cardiovasc Disord. 2024 Oct 26;24(1):591. doi: 10.1186/s12872-024-04264-5. PubMed 39462344 ↗
  • 郭金玉, 吕蓉, 张健, 等. 中文版Memorial心力衰竭症状评估量表的信效度评定[J]. 中华护理杂志, 2014,49(12): 1448-1452.
  • Turker E, Beduk T. Effect of an Educational Program Intervention for Caregivers of Heart Failure Patients on Patient Symptoms and Quality of Life: A Pretest-Posttest Study. West J Nurs Res. 2025 Nov;47(11):1036-1043. doi: 10.1177/01939459251359208. Epub 2025 Jul 31. PubMed 40742734 ↗
  • 郭金玉, 李峥, 康晓凤. 心力衰竭自我护理指数量表的汉化及信效度检测[J]. 中华护理杂志, 2012,47(07): 653-655.
  • Riegel B, Barbaranelli C, Carlson B, Sethares KA, Daus M, Moser DK, Miller J, Osokpo OH, Lee S, Brown S, Vellone E. Psychometric Testing of the Revised Self-Care of Heart Failure Index. J Cardiovasc Nurs. 2019 Mar/Apr;34(2):183-192. doi: 10.1097/JCN.0000000000000543. PubMed 30303894 ↗
  • Takahashi EA, Schwamm LH, Adeoye OM, Alabi O, Jahangir E, Misra S, Still CH; American Heart Association Council on Cardiovascular Radiology and Intervention, Council on Hypertension, Council on the Kidney in Cardiovascular Disease, and Stroke Council. An Overview of Telehealth in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2022 Dec 20;146(25):e558-e568. doi: 10.1161/CIR.0000000000001107. Epub 2022 Nov 14. PubMed 36373541 ↗
  • Krzesinski P, Jankowska EA, Siebert J, Galas A, Piotrowicz K, Stanczyk A, Siwolowski P, Gutknecht P, Chrom P, Murawski P, Walczak A, Szalewska D, Banasiak W, Ponikowski P, Gielerak G. Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study): a randomised controlled trial. Eur J Heart Fail. 2022 Mar;24(3):565-577. doi: 10.1002/ejhf.2358. Epub 2021 Oct 14. PubMed 34617373 ↗
  • Kitsiou S, Gerber BS, Buchholz SW, Kansal MM, Sun J, Pressler SJ. Patient-Centered mHealth Intervention to Improve Self-Care in Patients With Chronic Heart Failure: Phase 1 Randomized Controlled Trial. J Med Internet Res. 2025 Jan 15;27:e55586. doi: 10.2196/55586. PubMed 39813671 ↗
  • Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, Rienstra M, van den Heuvel MH, da Fonseca CA, Linssen GCM, Borleffs CJW, Boersma E, Asselbergs FW, Mosterd A, Brunner-La Rocca HP, de Boer RA; MONITOR-HF investigators. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. 2023 Jun 24;401(10394):2113-2123. doi: 10.1016/S0140-6736(23)00923-6. Epub 2023 May 20. PubMed 37220768 ↗
  • Simsek E, Korkmaz Y, Bozyel S, Guler A, Kocyigit Burunkaya D, Erturk M, Keser N. Digital Technologies in Heart Failure Management. Turk Kardiyol Dern Ars. 2024 Jan;52(1):52-60. doi: 10.5543/tkda.2023.79776. PubMed 38221836 ↗
  • Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, Tay WT, Dickstein K, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Lam CSP, Filippatos G, Collins SP. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health. 2020 Mar;8(3):e411-e422. doi: 10.1016/S2214-109X(20)30004-8. PubMed 32087174 ↗
  • Liu, H. M., Zhang, L. H.. Clinical characteristics, management, and outcome disparities of hospitalized patients with acute heart failure across different regions in China. Chin Circ J, 2024,39(6): 592-598.
  • Chinese Society of Cardiology, Chinese Medical Association; Chinese College of Cardiovascular Physician; Chinese Heart Failure Association of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2024]. Zhonghua Xin Xue Guan Bing Za Zhi. 2024 Mar 24;52(3):235-275. doi: 10.3760/cma.j.cn112148-20231101-00405. Chinese. PubMed 38514328 ↗

Individual participant data

Plan to share: Undecided — Individual participant data will not be made available due to privacy and ethical restrictions imposed by the institutional ethics committee. The data that support the findings of this study are available from the corresponding author upon reasonable request, subject to approval from the Ethics Committee of Peking University First Hospital.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07490470
Lead sponsor
Peking University First Hospital
Responsible party
YE Jing (Associate Chief Nurse, Peking University First Hospital) — Principal investigator
First posted
Mar 24, 2026
Start date
Jun 1, 2022
Primary completion
Jun 27, 2024
Completion
Jan 17, 2025
Last update
Mar 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion